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ABSTRACT 
Aims: Our proposal was to develop a vaccine based on total Leishmania antigens (TLA) adjuvanted 
with polyinosinic-polycytidylic acid [Poly(I:C)] able to induce a Th1 response which can provide 
protection against Leishmania infection. 
Methods and Results: Mice were vaccinated with two doses of TLA-Poly(I:C) administered by 
subcutaneous route at three week interval. Humoral and cellular immune responses induced by the 
immunization were measured. The protective efficacy of the vaccine was evaluated by challenging 
mice with infective promastigotes of Leishmania (Leishmania) amazonensis into the footpad. Mice 
vaccinated with TLA-Poly(I:C) showed a high anti-Leishmania IgG titer, as well as increased IgG1 and 
IgG2a subclass titers compared with mice vaccinated with the TLA alone. The high IgG2a indicated a 
Th1 bias response induced by the TLA-Poly(I:C) immunization. Accordingly, the cellular immune 
response elicited by the formulation was characterized by an increased production of IFN-γ and no 
significant production of IL-4. The TLA-Poly(I:C) immunization elicited good protection, which was 
associated with decreased footpad swelling, a lower parasite load and a reduced histopathological 
alteration in the footpad.  
Conclusion: Our findings demonstrate a promising vaccine against cutaneous leishmaniasis that is 
relatively economic and easy to develop and which should be taken into account for preventing 
leishmaniasis in developing countries. 
 
Keywords: adjuvant, leishmaniasis, parasite, vaccination 
 
INTRODUCTION 
Leishmaniasis is one of the most important neglected diseases which mainly affect the poorest 
populations with limited access to health care, located mainly in developing countries1. 
Unfortunately, there is no available vaccine to prevent this disease in humans2.  
First-generation vaccines are proposed as an economically affordable strategy to prevent 
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conducted by Convit et al. showed that a vaccine based on total antigens derived from 
promastigotes of Leishmania (Viannia) braziliensis killed by pasteurization and formulated with 
Bacillus Calmette-Guérin (BCG) as an adjuvant was safe and effective for treating leishmaniasis3. In 
2013, Mayrink et al. evaluated the efficacy and safety of a first-generation vaccine based on total 
antigens of L. (L.) amazonensis without adjuvant4. That work demonstrated a significant reduction in 
the incidence of the disease in vaccinated people, as compared to the placebo group. The study also 
showed that a vaccine formulation based on a single-species antigen of the genus Leishmania 
(single-species vaccine) can reduce the incidence of cutaneous leishmaniasis in the endemic area. 
Protection studies in Leishmania-murine models and the analysis of the immune profile of self-
healed individuals clearly indicate the need to induce a Th1 type response in order to obtain 
protection5,6. New adjuvants have been developed, offering multiple ways to modulate the immune 
response according to specific requirements7. 
Natural and synthetic double-stranded RNA (dsRNA), such as the synthetic Poly(I:C) adjuvant, act as 
Toll Like Receptor 3 agonist and induce the production of type I interferons (IFN) and other 
cytokines8,9. Poly(I:C) and other synthetic derivatives have been evaluated in animal and human 
clinical trials, demonstrating good efficacy and safety profiles10–12. 
In the present study, we investigated the potential adjuvant property of Poly(I:C) in a first-
generation vaccine formulated with L. (L.) amazonensis antigenic extract. We evaluated the ability of 
this formulation to mediate a Th1 immune response and to provide protective immunity against L. 
(L.) amazonensis infection in BALB/c mice. To the best of our knowledge, we demonstrate for the 
first time the use of Poly(I:C) as an effective adjuvant in a first-generation Leishmania vaccine. 
METHODS 
Animals  
Inbred female BALB/c mice (8-9 weeks old) were used in this study. Three independent experiments 
were carried out with five mice per group. All procedures were approved by the institutional animal 
care unit of Universidad de Cuyo (Protocol no. 80/ 2016). 
 
Parasites and antigenic Leishmania extract preparation 
Promastigotes of L. (L.) amazonensis (MHOM/VE/84/MEL) were grown and their infectivity was 
maintained by serial passage through mice, as described previously13. For the preparation of 
Leishmania extract, total Leishmania antigens (TLA) were obtained from promastigotes of L. (L.) 
amazonensis in late logarithmic phase. After that, promastigotes were harvested by centrifugation, 
washed three times with phosphate-buffered saline (PBS) and then disrupted by six to eight cycles of 
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Formulation and immunization schedule  
Mice received TLA alone (100 μg/mouse) (TLA) or formulated with high molecular weight Poly(I:C) 
(50 μg/mouse) (InvivoGen, San Diego, CA, USA) [TLA-Poly(I:C)]. Negative control groups received PBS 
and Poly(I:C) alone by subcutaneous route. For booster vaccination, mice received the same vaccine 
formulation three weeks after priming.  
Parasite challenge  
Immunized mice were challenged 15 days after the boost. The challenge was performed with 1 x 105 
of L. (L.) amazonensis promastigotes, which were injected into the right footpad (RFP). The infection 
development, represented as footpad swelling, was followed by measurement using a digital caliper 
during 11 weeks. The lesion size was calculated by subtracting the thickness value of the 
contralateral uninfected foot from that of the footpad thickness of the infected foot13. 
Measurement of humoral immune response 
Humoral immune responses induced by vaccinations were evaluated in serum samples 15 days after 
the boost. Antigen-specific total IgG, IgG1 and IgG2a subtypes were evaluated by enzyme-linked 
immunosorbent assay (ELISA), as described previously13. IgG titers are expressed as the reciprocal of 
highest serum dilution which yielded ELISA OD values two times the blank. 
Preparation of splenocytes and measurement of cellular immune responses 
Spleens were recollected aseptically from mice of each group 15 days after the boost. splenocytes 
were resuspended in supplemented RPMI 1640 medium (Invitrogen). The cells were cultured in 96-
well plates at a density of 2 × 105 cells/well. The cells were stimulated in vitro with TLA (1μg/well) 
and supernatants were collected after 72 h of incubation at 37°C with 5% CO2. Measurements of 
IFN-γ and IL-4 concentrations in the supernatants were carried out using OptEIA Kits (BD 
Pharmingen). 
Histopathological analysis 
The fragments of footpad lesion were fixed in Bouin's solution 4% and embedded in paraffin. 
Sections of 5–6 µm were stained with haematoxilin and eosin (H&E) for histopathological analysis. 
Images were taken with a Nikon Eclipse E200 Microscope (Nikon Corp., Japan) fitted with a 
Micrometric SE Premium (Nikon Corp., Japan) digital still camera. Histological damage was calculated 
from observation of 10 different fields (40X magnification) of H&E-stained sections from each 
animal. The histopathological score grading system was evaluated by the degree of inflammation as 
described by Côrtes DF14. The total score was defined as the sum of all scores.  
The parasite load in footpad lesions was performed as described by Rocha-Vieira et al.15, counting 
the number of parasites per field in 10 non-contiguous fields (magnification 630 X).  
Statistical analysis  
Differences between groups were tested for significance by  one-and-two way ANOVA followed by 
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RESULTS 
Humoral immune response elicited after immunization 
BALB/c mice were injected twice by subcutaneous route with the different vaccines in a period of 
three weeks. Fifteen days after the boost, the total anti-Leishmania IgG titer obtained by TLA-
Poly(I:C) was greater than that obtained by immunization with TLA (Figure 1 a). The IgG1 and IgG2a 
titers in mice immunized with TLA-Poly(I:C) reached values significantly higher than those obtained 
in the group of mice immunized with TLA (p <0.001). The inclusion of Poly(I:C) to ATL resulted in an 
increase of 6,7 and 7,8 fold in IgG1 and IgG2a titers respectively, compared with TLA (Figure 1 b). 
In accordance with these data, the IgG2a/IgG1 ratio of the TLA-Poly(I:C) group was of 1,42, polarizing 
the immune response toward a Th1 profile. 
 
Cellular immune response elicited after immunization 
In order to study the T helper cell cytokine profiles induced after vaccination, the main cytokines of 
Th1 (IFN-γ) and Th2 (IL-4) were determined in supernatants of spleen cells culture. 
IFN-γ was detected in significantly higher levels in antigen-stimulated spleen cells of mice vaccinated 
with TLA-Poly(I:C), as compared to the levels of mice vaccinated with TLA without adjuvant (Figure 1 
c). There was no significant difference in the production of IL-4 among all analyzed groups (Figure 1 
d). The high level of IFN-γ production by spleen cells in response to stimulation with L. (L.) 
amazonensis antigen  indicates that a strong Th1 immune response was generated in mice 
immunized subcutaneously with TLA-Poly(I:C).  
 
Protection assay of mice immunized with TLA-Poly(I:C) against challenge with L. (L.) amazonensis 
The mice vaccinated with TLA-Poly(I:C) showed good protection levels against cutaneous 
leishmaniasis, with a significant reduction in the size of the footpad lesion. On the other hand, 
immunization with TLA in the absence of adjuvant provided no protection against infection with L. 
(L.) amazonensis, resulting in swelling levels similar to those of non-vaccinated mice injected with 
PBS or Poly(I:C).The differences in the footpad thicknesses between the group receiving TLA alone 
and the group receiving TLA plus Poly(I:C) became statistically significant (p <0.05) by week 8 after 
challenge (Figure 1 e).  
 
Histopathology analysis of the tissue damage induced after challenge with L. (L.) amazonensis 
The analysis of the degree of inflammation of the footpad lesion indicated a significantly lower 
histological score index in the TLA-Poly(I:C) group compared to the TLA group. Accordingly, the 
parasite load in the footpad lesions of the TLA-Poly(I:C) group was approximately 3-5 fold lower (p 
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Despite extensive efforts, there is currently no effective vaccine for human leishmaniasis16. 
Although, the fact that many candidate antigens have been pinpointed in attempts to develop 
vaccines against Leishmania, only a first-generation vaccine formulated with BCG as adjuvant 
succeeded to reach phase III clinical trials17,18. Previous studies reported that an effective vaccine 
against leishmaniasis requires a multivalent cocktail of various antigens composed of a spectrum of 
protective epitopes which cover a broad range of MHC types in a population19.This fact is consistent 
with the leishmanization results, which indicate that crude Leishmania antigens such as TLA are 
appropriate candidates for vaccine development20,21. Mayrink et al. conducted a study in Brazil 
which showed a significant reduction in the incidence of the Leishmania infection in humans after 
immunization with a first-generation vaccine produced with TLA of L. (L.) amazonensis 
(IFLA/BR/67/PH8)4 .  
In the present study, we have evaluated the effectiveness of a first-generation vaccine containing 
whole L. (L.) amazonensis antigenic extract formulated with Poly(I:C), which has the ability to induce 
an immune response with a strong profile Th1, promoting antigen presentation, induction of IFN 
type I, and potent T cell immune responses22,23.  
First-generation vaccines are still a very attractive option for leishmaniasis control, especially in 
developing countries. The current approach in the development of whole parasite malaria vaccines 
is probably the best example of the possibilities of first-generation vaccines. This approach has 
generated vaccines capable of inducing high-grade protection by parenteral administration24. 
Our results demonstrate for the first time that the subcutaneous administration of TLA formulated 
with Poly(I:C) promotes a protective immune response against cutaneous leishmaniasis. This 
immune response was characterized by a high IgG titer (Figure 1 a), as well as high IgG1 and IgG2a 
subtype titers (Figure 1 b). In this work, the immunization with TLA-Poly(I:C) resulted in high titer of 
IgG2a, which is correlated with a dominate Th1 profile. Accordingly with this observation, the TLA-
Poly(I:C) formulation triggered a cellular immune response characterized by a high production of 
IFN-γ (5.829 pg/ml) and very low levels of IL-4 (20 pg/ml) (Figure 1 c and d ). 
 Results demonstrated that immunization with TLA-Poly(I:C) induced a strong specific Th1-type 
response, which conferred protection against infection with L. (L.) amazonensis in mice (Figure 1 e, 
and Table 1).  
In conclusion, Poly(I:C) is a promising candidate for the development of a new Leishmania vaccine 
due to its safety and ability to induce a protective Th1 immune response. It would be important to 
conduct further research on the potential use of Poly(I:C) as an adjuvant and the mechanisms 
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Table 1: Histopathological score indexes and parasite load of the footpad infection site of the 
different vaccinated groups after eleven weeks post-challenge with L. (L.) amazonensis 
(MHOM/VE/84/MEL). 
                                 Histopathological score index                         Parasite load (no. parasites/field) 
PBS                                            26,66 ± 3,055                                                             494,1 ± 175,7 
TLA                                            27,66 ± 2,517                                                             608,4 ± 102,9 
TLA-Poly (I:C)                          18,33 ± 4,163**                                                         298,6 ± 85,71*** 
Poly (I:C)                                  22,66 ± 3,215                                                             546,7 ± 137 




Figure 1: Humoral immune responses: Anti-Leishmania IgG and IgG subtypes antibodies response in 
mice vaccinated with two doses (at 3 weeks interval) of: PBS, TLA, TLA-Poly(I:C) and Poly(I:C) alone. 
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(c) IFN-γ and (d) IL-4 were determined in splenocytes culture in vitro, stimulated with TLA (1μg/well) 
or without stimulation. Protection assay: (e) Footpad swelling caused by challenge with infective 
promastigotes of L. (L.) amazonensis in BALB/c mice vaccinated with PBS, TLA, Poly(I:C) and TLA-
Poly(I:C). p-values: *, p <0.05; ** p <0.01,***,p <0.001.  
 
 
 
